Proteomics

Dataset Information

0

Proteomic anlaysis of Fabry iPSC derived cardiomyocytes treated with GLA modRNA


ABSTRACT: Recent studies in non-human model systems have shown therapeutic potential of modified mRNA (modRNA) treatments for lysosomal storage diseases. Here, we assessed the efficacy of a modRNA treatment to restore the expression of the α-galactosidase (GLA) gene in a human cardiac model generated from induced-pluripotent stem cell-derived from two patients with Fabry disease. In line with the clinical phenotype, cardiomyocytes from Fabry patient’s induced pluripotent stem cells show accumulation of the glycosphinolipid Globotriaosylceramide (GB3), which is an α-galactosidase substrate. Further, the patient-specific cardiomyocytes have significant upregulation of lysosomal associated proteins. Upon modRNA treatment, a subset of lysosomal proteins were partially restored to wildtype levels, implying the rescue of the molecular phenotype associated with the Fabry genotype. Importantly, a significant reduction of GB3 levels was observed in GLA modRNA treated cardiomyocytes demonstrating that α-galactosidase enzymatic activity was restored. Together, our results validate the utility of patient IPSC-derived cardiomyocytes as a model to study disease processes in Fabry disease and the therapeutic potential of GLA modRNA treatment to reduce GB3 accumulation in the heart.

INSTRUMENT(S): Orbitrap Exploris 480

ORGANISM(S): Homo Sapiens (human)

TISSUE(S): Cell Culture

SUBMITTER: Benjamin Parker  

LAB HEAD: Benjamin Parker

PROVIDER: PXD038361 | Pride | 2023-07-20

REPOSITORIES: Pride

Similar Datasets

2022-06-10 | PXD032937 | Pride
2023-10-24 | PXD043096 | Pride
2024-02-07 | PXD043659 | Pride
2024-02-28 | PXD038185 | Pride
2024-03-22 | PXD047762 | Pride
2022-01-06 | PXD026051 | Pride
2023-07-20 | PXD040084 | Pride
2024-03-21 | PXD046510 | Pride
2023-06-09 | PXD037586 | Pride
2019-09-25 | PXD013160 | Pride